Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD.

PLoS One. 2012;7(2):e31962. doi: 10.1371/journal.pone.0031962. Epub 2012 Feb 16.

2.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM.

J Exp Med. 2005 May 16;201(10):1591-602. Epub 2005 May 9.

4.

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.

Cancer Res. 2001 Feb 1;61(3):880-3.

5.

Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.

Black CM, Armstrong TD, Jaffee EM.

Cancer Immunol Res. 2014 Apr;2(4):307-19. doi: 10.1158/2326-6066.CIR-13-0145. Epub 2014 Jan 17.

6.

HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.

Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR.

J Immunol. 2003 Oct 15;171(8):4054-61.

7.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

8.

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM.

Cancer Res. 2000 Jul 1;60(13):3569-76.

9.

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM.

J Immunol. 2011 Apr 1;186(7):3847-57. doi: 10.4049/jimmunol.1000361. Epub 2011 Feb 23.

10.

Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.

Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ.

J Immunol. 2009 May 1;182(9):5873-81. doi: 10.4049/jimmunol.0804074.

11.
12.
13.

Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML.

Clin Cancer Res. 2007 Mar 15;13(6):1883-91.

14.

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.

Gritzapis AD, Voutsas IF, Baxevanis CN.

Cancer Immunol Immunother. 2012 Mar;61(3):397-407. doi: 10.1007/s00262-011-1113-4. Epub 2011 Sep 18.

PMID:
21928125
16.

The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic mice.

Burgents JE, Moran TP, West ML, Davis NL, Johnston RE, Serody JS.

J Immunother. 2010 Jun;33(5):482-91. doi: 10.1097/CJI.0b013e3181d756bb.

PMID:
20463599
17.

Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.

Xie Y, Chen Y, Ahmed KA, Li W, Ahmed S, Sami A, Chibbar R, Tang X, Tao M, Xu J, Xiang J.

Cancer Gene Ther. 2013 Oct;20(10):590-8. doi: 10.1038/cgt.2013.60. Epub 2013 Sep 20.

PMID:
24052129
18.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT.

J Immunol. 2006 Jan 15;176(2):974-83.

19.

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM.

J Immunol. 2003 Apr 15;170(8):4273-80.

20.

The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.

Lustgarten J, Dominguez AL, Cuadros C.

Eur J Immunol. 2004 Mar;34(3):752-761. doi: 10.1002/eji.200324427.

Supplemental Content

Support Center